Candesartan/HCT 32/25 mg
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Candesartan/HCT 32/25 mg, covering 2009-06-17 to 2009-06-17. Get the full timeline:
Most recent: Clinical Trial Update: Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo [Phase 3]